IM Cannabis Corp.
IMCC Healthcare Drug Manufacturers Specialty & Generic
IM Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue fell 40.3%, EPS fell 385.7%, free cash flow fell 266.8% and total debt fell 64.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow IMCC
IM Cannabis Corp. (IMCC) EV/Sales
As of 16 October 2026, IM Cannabis Corp. (IMCC) trades at a EV/Sales of 0.0×. Over the past ten years it has ranged from 0.0× (December 2020) to 32.7× (March 2021); the current reading is higher than 12% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.1× | (28.99%) |
| FY2024 | 0.2× | (46.24%) |
| FY2023 | 0.3× | (5.23%) |
| FY2022 | 0.3× | (93.03%) |
| FY2021 | 4.7× | (81.06%) |
| FY2020 | 24.8× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.0× | (42.09%) |
| Mar 2026 | 0.1× | (44.97%) |
| Dec 2025 | 0.1× | (50.00%) |
| Sep 2025 | 0.2× | 0.77% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GELS Gelteq Limited compare | n/m |
| AKAN Akanda Corp. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| IMCC IM Cannabis Corp. | 0.0× |
| YCBD cbdMD, Inc. compare | 0.2× |
| PTPI Petros Pharmaceuticals, Inc. compare | 0.4× |
| NEPTF Neptune Wellness Solutions Inc. compare | 1.1× |
| RDHL Redhill Biopharma Ltd. compare | 6.4× |
| BTAIQ BioXcel Therapeutics, Inc. compare | 228× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)